Companies ›Healthcare ›DVM.HN

DVM.HN — — Pharmaceuticals

Dvm.Hn

$7 000,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

3,5 %

ROE

5,1 %

Net margin

2,8 %

Debt / equity

0,71

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

DVM.HN operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Business. DVM.HN operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

5,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning DVM.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to DVM.HN. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

DVM.HN operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

DVM.HN maintains a capital structure with a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 0.99, suggesting that its current liabilities are nearly equal to its current assets. Despite a strong operating cash flow of 1,123,955,582,010 VND, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, DVM.HN's return on equity (ROE) is 5.15%, and its return on assets (ROA) is 2.42%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of generating returns for shareholders and asset utilization.

Geographically and segment-wise, DVM.HN's revenue concentration is not disclosed in the available data. However, the company's exposure to pharmaceuticals is broad, with no specific segments or regions highlighted as dominant contributors to revenue.

The company's growth trajectory is not explicitly outlined in the available data. However, the operating cash flow and net income figures suggest a stable financial performance, with no significant year-over-year changes reported. The absence of detailed growth projections or segment-specific outlooks limits the ability to assess future performance with certainty.

DVM.HN's risk profile is marked by a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in meeting short-term obligations. The low dilution risk indicates that the company is not expected to issue additional shares in the near term, preserving the value of existing shareholders' equity.

Recent events and filings for DVM.HN are not detailed in the available data. The company's financial statements and risk assessments do not provide specific information on recent strategic moves, regulatory changes, or market developments that could impact its operations.

Key takeaways

DVM.HN has a moderate debt-to-equity ratio of 0.71, indicating a balanced capital structure.
The company's ROE of 5.15% and ROA of 2.42% are below industry medians, suggesting underperformance in profitability.
DVM.HN's liquidity position is medium, with a current ratio of 0.99, indicating potential short-term financial constraints.
The company's risk profile is characterized by medium liquidity risk and low dilution risk.
DVM.HN's growth trajectory is not clearly defined, with no significant year-over-year changes in financial performance.
Recent events and strategic developments for DVM.HN are not detailed in the available data.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$7 000,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$776.02B

Net cashⓘ

-$441.51B

Current ratioⓘ

1.0

Debt / equityⓘ

0.7

ROAⓘ

2.4%

ROEⓘ

5.1%

Cash conversionⓘ

2813.0%

CapEx / revenueⓘ

-0.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin3,5 %Below median

Net Margin2,8 %Below median

ROE5,1 %Above median

Capex / Rev-0,0 %Above P75

D/E0,71Bottom quartile

Cash Conv28,13Best in class

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

DVM.HN Market data — financials · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

DVM.HNCanonical

— · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread